Formulated for type 2 diabetes mellitus to manage blood sugar and support glycemic control.
Mechanism of Action
Glipizide stimulates the release of insulin from pancreatic beta cells. Metformin reduces hepatic glucose production and enhances insulin sensitivity in peripheral tissues. Together, they target multiple physiological pathways of type 2 diabetes.
Route of Administration
Oral
Onset Time
1–2 weeks
Duration
12–24 hours
Contraindications
Severe renal impairment, Metabolic acidosis, Hypersensitivity to glipizide or metformin
Severe Adverse Events
Lactic acidosis, Hepatotoxicity, Severe hypoglycemia — requires immediate medical attention
Information related to Metaglip is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
